July 19, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-7561
Ladies and Gentlemen:
We have read Vaxart, Inc.'s statements included under Item 4.01 of its Form 8‑K dated July 19, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K.
Very truly yours,
/s/ OUM & Co. LLP
Attachments
- Original document
- Permalink
Disclaimer
Vaxart Inc. published this content on 20 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 20 July 2021 10:03:10 UTC.